TRDAEntrada Therapeutics, Inc.
Earnings
When Entrada Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.
27 quarters. Mar 31, 2020 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Feb 25, before the open
Thu, Feb 25, 2027in 99 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 23 – Mar 18
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $1.30M
- Revenue, change from a year earlier: Q3 2026 −43.9%, Q2 2026 −53.9%, Q1 2026 −95.7%, Q4 2025 −96.5%
- Net income
- -$39.16M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- $905.00K
- −43.9%
- Net income
- -$39.74M
- N/M
- EPS
- -$0.94
- N/M
- Revenue
- $898.00K
- −53.9%
- Net income
- -$42.76M
- N/M
- EPS
- -$1.01
- N/M
- Revenue
- $875.00K
- −95.7%
- Net income
- -$39.72M
- N/M
- EPS
- -$0.95
- N/M
- Revenue
- $1.30M
- −96.5%
- Net income
- -$39.16M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 5, 2026 · pre-market | Nov 5, 2026 | 36 d | 10-Q | $905.00K | −43.9% | -$0.94 | 10.1% | |
| Q2 2026 | Jun 30, 2026 | Aug 5, 2026 · pre-market | Aug 5, 2026 | 36 d | 10-Q | $898.00K | −53.9% | -$1.01 | 2.3% | |
| Q1 2026 | Mar 31, 2026 | May 7, 2026 · pre-market | May 7, 2026 | 37 d | 10-Q | $875.00K | −95.7% | -$0.95 | 57.0% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Feb 26, 2026 · pre-market | Feb 26, 2026 | 57 d | 10-K | $1.30M | −96.5% | — | +6.4% | |
| Q3 2025 | Sep 30, 2025 | Nov 6, 2025 · pre-market | Nov 6, 2025 | 37 d | 10-Q | $1.61M | −91.8% | -$1.06 | +1.4% | |
| Q2 2025 | Jun 30, 2025 | Aug 6, 2025 · pre-market | Aug 6, 2025 | 37 d | 10-Q | $1.95M | −97.9% | -$1.04 | +2.3% | |
| Q1 2025 | Mar 31, 2025 | May 8, 2025 · pre-market | May 8, 2025 | 38 d | 10-Q | $20.56M | −65.2% | -$0.42 | +5.7% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Feb 27, 2025 · pre-market | Feb 27, 2025 | 58 d | 10-K | $37.40M | −10.6% | — | +0.5% | |
| Q3 2024 | Sep 30, 2024 | Nov 5, 2024 · pre-market | Nov 5, 2024 | 36 d | 10-Q | $19.57M | −55.3% | -$0.35 | +4.8% | |
| Q2 2024 | Jun 30, 2024 | Aug 13, 2024 · pre-market | Aug 13, 2024 | 44 d | 10-Q | $94.69M | +421.2% | $1.55 | +14.4% | |
| Q1 2024 | Mar 31, 2024 | May 7, 2024 · pre-market | May 7, 2024 | 37 d | 10-Q | $59.12M | +134.0% | $0.68 | +6.4% | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Mar 13, 2024 · pre-market | Mar 13, 2024 | 73 d | 10-K | $41.85M | — | — | — | |
| Q3 2023 | Sep 30, 2023 | Nov 7, 2023 · pre-market | Nov 7, 2023 | 38 d | 10-Q | $43.74M | — | $1.02 | +8.6% | |
| Q2 2023 | Jun 30, 2023 | Aug 8, 2023 · pre-market | Aug 8, 2023 | 39 d | 10-Q | $18.17M | — | -$0.78 | +10.5% | |
| Q1 2023 | Mar 31, 2023 | May 10, 2023 · pre-market | May 10, 2023 | 40 d | 10-Q | $25.26M | — | -$0.21 | 1.6% | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Mar 6, 2023 · pre-market | Mar 6, 2023 | 65 d | 10-K | — | — | — | +1.4% | |
| Q3 2022 | Sep 30, 2022 | Nov 7, 2022 · pre-market | Nov 7, 2022 | 38 d | 10-Q | $0.00 | — | -$0.80 | 9.3% | |
| Q2 2022 | Jun 30, 2022 | — | Aug 11, 2022 | 42 d | 10-Q | $0.00 | — | -$0.74 | +0.7% | |
| Q1 2022 | Mar 31, 2022 | May 12, 2022 · pre-market | May 12, 2022 | 42 d | 10-Q | $0.00 | — | -$0.69 | +10.2% | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | Mar 15, 2022 · pre-market | Mar 15, 2022 | 74 d | 10-K | — | — | — | +6.0% | |
| Q3 2021 | Sep 30, 2021 | Dec 9, 2021 · pre-market | Dec 9, 2021 | 70 d | 10-Q | — | — | -$9.78 | 5.9% | |
| Q2 2021 | Jun 30, 2021 | — | — | — | — | — | — | -$7.56 | — | |
| Q1 2021 | Mar 31, 2021 | — | — | — | — | — | — | -$6.67 | — | |
| FY 2020 | ||||||||||
| Q4 2020derived | Dec 31, 2020 | — | — | — | — | — | — | — | — | |
| Q3 2020 | Sep 30, 2020 | — | — | — | — | — | — | -$6.13 | — | |
| Q2 2020 | Jun 30, 2020 | — | — | — | — | — | — | — | — | |
| Q1 2020 | Mar 31, 2020 | — | — | — | — | — | — | — | — | |
Earlier years, FY 2020 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Entrada Therapeutics, Inc. · CIK 1689375 · Engraved from SEC EDGAR